Cellestia to start Phase I/IIa of CB-103 for Notch-dependent cancers

Cellestia Biotech AG (Basel, Switzerland) said it received Spanish regulatory approval to start an open-label Phase I/IIa trial of CB-103 to treat adults with Notch (NOTCH)-dependent advanced or metastatic solid tumors and hematological malignancies. The company expects the first patients to be treated next quarter. The primary endpoint of the Phase I part is to determine the maximum tolerated dose (MTD) or recommended Phase II dose. The purpose of the Phase IIa part is to assess safety and single agent preliminary efficacy in patients with confirmed NOTCH-positive cancers. The trial will also evaluate pharmacokinetics and biomarkers...